MilliporeSigma Helps Accelerate Global Access to Affordable Vaccines

On Apr 13, 2018

MilliporeSigma announced a partnership with Oxford University’s Jenner Institute to develop more robust and scalable vaccine manufacturing processes. This partnership, as well as plans to develop a vaccine manufacturing facility in Ghana, further the company’s commitment to improving global health by making vaccines more affordable and available.

In addition to collaborating with the Jenner Institute, Merck is planning a vaccine manufacturing facility in Ghana to help address significant health challenges in a continent that imports 99 percent of its vaccines. (Source: Merck)

“This collaboration with the Jenner Institute will facilitate access to affordable vaccines while improving the global response to disease outbreaks,” said Udit Batra, CEO of MilliporeSigma. “MilliporeSigma is committed to expanding access to advanced drug therapies, especially in low- and middle-income countries. Together, with our partners, we have shaped how vaccine production is done today and are helping to solve the toughest problems of tomorrow.”

Through the collaboration with the Jenner Institute, the partners will improve the manufacturing process for adenovirus vaccines — vaccines based on adenovirus, a type of DNA virus, as a carrier — using MilliporeSigma products, systems and technologies on a real-world feed stream. By applying MilliporeSigma technology, the collaborators aim to develop a cost-effective and transferable manufacturing process that can be used to accelerate vaccine development and manufacturing worldwide.

“MilliporeSigma is an excellent partner for enhancing our capabilities in adenovirus vaccine development, as the newly developed process should match or exceed our existing process in terms of productivity and purity,” said Adrian Hill, director of the Jenner Institute at Oxford University.

The collaboration should result in a closed process that can be practiced in a cleanroom to minimize contamination, in line with the high biological safety requirements for viral vectors.

“Such improvements should help advance the development of clinical-grade, injectable drug product for use in clinical trials and other research applications,” Hill added.

MilliporeSigma building vaccine facility in Ghana

Separately, MilliporeSigma is developing plans for a vaccine manufacturing facility in Ghana, helping to address significant health challenges in a continent that imports 99 percent of its vaccines. Working with Ridge Management Solutions and other partners, a recently signed memorandum of understanding between MilliporeSigma and Ridge provides the opportunity for Ghana to become the first country in Sub-Saharan Africa to have a dedicated human vaccine manufacturing factory.

“We want to support emerging economies by sharing our expertise, helping them streamline their manufacturing processes while supporting technology transfer and local facility startup,” Batra added.